Yes

Liposomes, including multilamellar vesicles, can encapsulate both hydrophilic and lipophilic drugs, allowing for diverse therapeutic agent delivery. Their structure enables hydrophilic drugs to be loaded into the aqueous core and lipophilic drugs to associate with the lipid bilayer.

Yes, different drugs can be loaded into a multilamellar vesicle (MLV) liposome. MLVs, due to their multiple concentric lipid bilayers, provide distinct compartments for encapsulating both hydrophilic and hydrophobic drugs. However, factors such as drug compatibility, encapsulation efficiency, and release kinetics must be carefully optimized. Techniques like passive loading, active loading (pH gradient or ion gradient methods), and surface modifications can enhance drug loading and targeting capabilities.

Multilamellar liposomes (MLVs) can indeed be loaded with multiple drugs simultaneously, enabling versatile applications in combination therapy. These vesicles consist of concentric phospholipid bilayers separated by aqueous compartments, allowing for the encapsulation of both hydrophobic and hydrophilic compounds. Hydrophobic drugs (such as paclitaxel or curcumin) incorporate into the lipid bilayer itself, while hydrophilic drugs (like doxorubicin or cisplatin) are trapped in the aqueous layers between the membranes. Amphiphilic drugs may partition between both phases. The loading efficiency can be optimized through passive encapsulation or active loading techniques like pH-gradient methods. A key advantage of MLVs is their ability to deliver drug combinations synergistically while controlling release kinetics—outer layers release their payload first while inner layers provide sustained release. This architecture also helps reduce systemic toxicity by shielding drugs until they reach the target site. However, challenges include potential drug-drug interactions that could cause aggregation or instability, which may be addressed by strategic loading into separate compartments or using stabilizing additives like cholesterol or PEGylated lipids. Practical examples include cancer therapy combinations (e.g., doxorubicin with paclitaxel) or antimicrobial formulations (e.g., ciprofloxacin with silver nanoparticles). Characterization of drug-loaded MLVs typically involves techniques like UV-Vis/HPLC for encapsulation efficiency measurements, dialysis studies for release profiling, and cryo-TEM for structural verification.